The stock price of CERo Therapeutics Holdings Inc (NASDAQ: CERO) has dropped by -7.98 compared to previous close of 0.19. Despite this, the company has seen a fall of -18.57% in its stock price over the last five trading days. globenewswire.com reported 2024-11-15 that SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML).
Is It Worth Investing in CERo Therapeutics Holdings Inc (NASDAQ: CERO) Right Now?
Additionally, the 36-month beta value for CERO is 0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CERO is 26.22M and currently, short sellers hold a 29.99% ratio of that float. The average trading volume of CERO on December 03, 2024 was 65.17M shares.
CERO’s Market Performance
CERO’s stock has seen a -18.57% decrease for the week, with a 106.99% rise in the past month and a 53.90% gain in the past quarter. The volatility ratio for the week is 28.12%, and the volatility levels for the past 30 days are at 26.76% for CERo Therapeutics Holdings Inc. The simple moving average for the past 20 days is -1.74% for CERO’s stock, with a -78.93% simple moving average for the past 200 days.
CERO Trading at 39.85% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.61% of loss for the given period.
Volatility was left at 26.76%, however, over the last 30 days, the volatility rate increased by 28.12%, as shares surge +113.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.24% upper at present.
During the last 5 trading sessions, CERO fell by -18.57%, which changed the moving average for the period of 200-days by -96.38% in comparison to the 20-day moving average, which settled at $0.1807. In addition, CERo Therapeutics Holdings Inc saw -98.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERO starting from SLOAN STUART M, who sale 532,486 shares at the price of $0.10 back on Sep 25 ’24. After this action, SLOAN STUART M now owns 21,067,956 shares of CERo Therapeutics Holdings Inc, valued at $55,538 using the latest closing price.
YK Bioventures Opportunities G, the 10% Owner of CERo Therapeutics Holdings Inc, sale 3,250,000 shares at $0.10 during a trade that took place back on Oct 10 ’24, which means that YK Bioventures Opportunities G is holding 22,620,783 shares at $325,000 based on the most recent closing price.
Stock Fundamentals for CERO
The total capital return value is set at 4.94. Equity return is now at value -4090.08, with -108.70 for asset returns.
Based on CERo Therapeutics Holdings Inc (CERO), the company’s capital structure generated -0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -98.97. The debt to equity ratio resting at -0.03. The interest coverage ratio of the stock is -543.93.
Currently, EBITDA for the company is -2.44 million with net debt to EBITDA at 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In conclusion, CERo Therapeutics Holdings Inc (CERO) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
